Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Oncology|August 21, 2008
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choiceChiara Catania, Tommaso De Pas, Aron Goldhirsch, et al.
Cancer Treatment Reviews|August 11, 2020
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published dataAntonio Passaro, Ilaria Attili, Stefania Morganti, et al.
Breast Cancer Research and Treatment|September 13, 2005
Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancerChiara Catania, Florence Didier, Maria Elena Leon, et al.
Oncotargets and Therapy|August 29, 2015
Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)Gianluca Spitaleri, Roberto Biffi, Massimo Barberis, et al.
Critical Reviews in Oncology/Hematology|October 26, 2013
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic optionsChiara Lazzari, Gianluca Spitaleri, Chiara Catania, et al.
Frontiers in Oncology|August 29, 2022
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50Ilaria Attili, Carmine Valenza, Celeste Santoro, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature ReviewNunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, et al.
Clinical Breast Cancer|April 6, 2006
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancerFranco Nolè, Chiara Catania, Elisabetta Munzone, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2013
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungFabio Conforti, Chiara Catania, Francesca Toffalorio, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2006
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patientsTommaso De Pas, Carlo Putzu, Giuseppe Curigliano, et al.
Pageof 8